Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050063 · ClinicalTrials.gov registry record
Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 78
- Enrollment target
NCT00050063: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00050063 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 78 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050063 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 78 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether therapeutic HIV vaccines can help the immune system control HIV viral load after anti-HIV drugs are discontinued.
Interventions
- BIOLOGICAL Therapeutic vaccinations from A5058s
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Est. Completion | 2004-05 |
What the finished NCT00050063 record still lists
NCT00050063 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 78 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Therapeutic vaccinations from A5058s is the first listed.
NCT00050063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00050063 about?
NCT00050063 is a clinical study titled "Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs". The purpose of this study is to determine whether therapeutic HIV vaccines can help the immune system control HIV viral load after anti-HIV drugs are discontinued.
What is the current status of trial NCT00050063?
This trial is currently completed. The enrollment target is 78 participants. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00050063?
The interventions under investigation include: Therapeutic vaccinations from A5058s (BIOLOGICAL).
Who is sponsoring clinical trial NCT00050063?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer